title: Influence of low-level laser associated with osteogenic proteins recombinant human BMP-2 and Hevea brasiliensis on bone repair in Wistar rats.
abstract: This study analyzed the newly formed bone tissue after application of recombinant human BMP-2 (rhBMP-2) and P-1 (extracted from Hevea brasiliensis) proteins, 2 weeks after the creation of a critical bone defect in male Wistar rats treated or not with a low-intensity laser (GaAlAs 780 nm, 60 mW of power, and energy density dose of 30 J/cm(2)). The animals were divided into two major groups: (1) bone defect plus low-intensity laser treatment and (2) bone defect without laser irradiation. The following subgroups were also analyzed: (a) 5 μg of pure rhBMP-2; (b) 5 μg of pure P-1 fraction; (c) 5 μg of rhBMP-2/monoolein gel; (d) 5 μg of P-1 fraction/monoolein gel; (e) pure monoolein gel. Comparisons of the groups receiving laser treatment with those that did not receive laser irradiation show differences in the areas of new bone tissue. The group treated with 5 μg of rhBMP-2 and laser irradiation was not significantly different (P >0.05) than the nonirradiated group that received the same treatment. The irradiated, rhBMP-2/monoolein gel treatment group showed a lower area of bone formation than the nonirradiated, rhBMP-2/gel monoolein treatment group (P < 0.001). The area of new bone tissue in the other nonirradiated and irradiated groups was not significantly different (P > 0.05). Furthermore, the group that received the 5 μg of rhBMP-2 application showed the greatest bone formation. We conclude that the laser treatment did not interfere with the area of new bone tissue growth and that the greatest stimulus for bone formation involved application of the rhBMP-2 protein.
authors.affiliation: Departamento de Morfologia, Estomatologia e Fisiologia, Faculdade de Odontologia de Ribeirão Preto, Universidade de São Paulo, Av. Café S/N, CEP: 14040-904, Monte Alegre, Ribeirão Preto, SP. mamieiyo@forp.usp.br
authors.forename: Mamie Mizusaki
authors.initials: MM
authors.lastname: Iyomasa
authors.forename: João Paulo Mardegan
authors.initials: JP
authors.lastname: Issa
authors.forename: Mirella Lemos
authors.initials: ML
authors.lastname: de Queiróz Tavares
authors.forename: Yamba Carla Lara
authors.initials: YC
authors.lastname: Pereira
authors.forename: Maria Bernadete Sasso
authors.initials: MB
authors.lastname: Stuani
authors.forename: Fabíola
authors.initials: F
authors.lastname: Mishima
authors.forename: Joaquim
authors.initials: J
authors.lastname: Coutinho-Netto
authors.forename: Walter
authors.initials: W
authors.lastname: Sebald
mesh_terms: D000818:Animals; D055396:Bone Morphogenetic Protein 2 / Q000008:administration & dosage / Q000494:pharmacology*; D005989:Glycerides / Q000008:administration & dosage; D028482:Hevea / Q000737:chemistry*; D006801:Humans; D007150:Immunohistochemistry; D028022:Low-Level Light Therapy; D008297:Male; D010012:Osteogenesis / Q000187:drug effects* / Q000528:radiation effects; D010294:Parietal Bone / Q000187:drug effects* / Q000293:injuries; D010940:Plant Proteins / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D012887:Skull Fractures / Q000188:drug therapy / Q000532:radiotherapy; D016212:Transforming Growth Factor beta / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D055396:Bone Morphogenetic Protein 2; D005989:Glycerides; D010940:Plant Proteins; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2; C005953:monoolein